Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
12 studies found for:    cG250
Show Display Options
Rank Status Study
1 Completed
Has Results
Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: 111-In-DOTA-cG250;   Drug: 177-Lu-DOTA-cG250
2 Terminated Study of Safety and Effects of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Biological: Chimeric monoclonal antibody cG250;   Drug: Sunitinib malate
3 Completed Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
Conditions: Cancer of Kidney;   Kidney Cancer;   Renal Cancer;   Neoplasms, Kidney;   Renal Neoplasms
Intervention: Drug: 124-Iodine-cG250 (124I-cG250)
4 Completed Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250
Condition: Clear Cell Renal Cell Carcinoma
Interventions: Drug: Sorafenib;   Drug: 111Indium-bevacizumab;   Drug: 111Indium-cG250
5 Recruiting Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
Condition: Renal Cancer
Intervention: Drug: 124IcG250
6 Completed
Has Results
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
Conditions: Renal Cell Carcinoma;   Kidney Cancer
Interventions: Drug: 124-Iodine-cG250 (124I-cG250);   Procedure: CT
7 Unknown  Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250
Conditions: Renal Cell Carcinoma;   Kidney Neoplasm;   Renal Cancer;   Kidney Cancer
Intervention: Drug: Yttrium-90 conjugated chimeric G250 (90Y-cG250)
8 Completed Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: girentuximab;   Other: placebo
9 Completed Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
Condition: Kidney Cancer
Intervention: Radiation: iodine I 131 chimeric monoclonal antibody G-250
10 Completed Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
Condition: Metastatic Clear Cell Renal Cell Carcinoma
Intervention: Drug: Lu-177-DOTA-girentuximab
11 Not yet recruiting REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
Conditions: Renal Cell Carcinoma;   Kidney Cancer
Intervention: Drug: Iodine (124I) Girentuximab
12 Completed Brivanib Metastatic Renal Cell Carcinoma
Condition: Male and Female Subjects 18 Years of Age and Older With Metastatic Renal Cell Carcinoma. Eligible Patients Must Have Undergone and Failed Prior Treatment.
Interventions: Drug: Brivanib alaninate;   Genetic: Polymerase chain reaction;   Other: Iodine I 124 chimeric monoclonal antibody G250;   Procedure: Positron emission tomography/computed tomography;   Genetic: Protein expression analysis;   Other: Immunohistochemistry

Study has passed its completion date and status has not been verified in more than two years.